Anthrax research might provide more time for treatment

TROY, N.Y. Researchers at Rensselaer Polytechnic Institute in Troy, N.Y., have been awarded new federal grant money to develop experimental compounds that may someday extend the period during which a person exposed to anthrax can be treated successfully. Ravi Kane, assistant professor of chemical and biological engineering at Rensselaer has been awarded a grant of $500,000 from the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to develop inhibitors of the anthrax toxin. The inhibitors will be tested in collaboration with Dr. Jeremy Mogridge at the University of Toronto.

The potentially deadly disease anthrax is caused by a toxin secreted by the spore-forming bacterium Bacillus anthracis. Antibiotics can kill the bacteria and, started early enough, offer successful treatment in many cases. Standard antibiotic treatment has no effect on the amount of toxin that builds up in the blood over time, however, making speedy treatment crucial.

Standing in the Way of Infection

"An effective anthrax inhibitor would be able to prevent the toxin from binding to receptors on the human cell, thereby hindering the toxin from doing any damage," Kane said. Unlike antibiotics, which can kill the bacteria but do not affect the toxin, an inhibitor also would be able to reduce levels of toxin that have been released into the body. Once levels of toxin have been lowered, standard antibiotic treatment also would be administered to kill all remaining bacteria. "Combined with standard antibiotic treatment, a toxin inhibitor would enable the successful treatment of anthrax at later stages of the disease and allow many more lives to be saved," Kane said.

New Option for Prevention

Heightened awareness of the ability to deliver anthrax spores through the air, combined with the high mortality rate of the inhaled form of the disease, has led to the use of the spores as a biological weapon. An anthrax v

Contact: Joely Johnson
Rensselaer Polytechnic Institute

Page: 1 2

Related biology news :

1. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
2. Anthrax spores can germinate, grow and reproduce in soil
3. Anthrax: A soil bug gone bad
4. Anthrax threat needs aggressive government action plan, say researchers
5. Anthrax drugs used to treat adults can treat children, too
6. CDC MMWR: Fetal Alcohol Syndrome and Cutaneous Anthrax in a Lab Worker
7. Anthrax spores use failsafe protection system, say U-M scientists
8. Anthrax genome may contain new clues to fight infection, says Science Functional Genomics article
9. Anthrax dectectors are coming
10. Anthrax - Trail of terror
11. Anthrax - How to protect ourselves

Post Your Comments:

(Date:11/2/2019)... ... 2019 , ... Stay on top of current hot topics through free webinars ... webinars is free, so be sure to register today to save your place! Participate ... to see our upcoming webinars: , CLINICAL OPERATIONS , November 14 – Leveraging Technology ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., the leading blockchain ... Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. The new investment ... accelerate its position as the leading data provider of institutional-grade blockchain and cryptoasset ...
(Date:10/27/2019)... ... October 26, 2019 , ... Since 2010, The HOTH has served over ... the success of their clients, they’ve earned a place on the highly-competitive and desirable ... won many additional awards and accolades along the way. , Now, The HOTH ...
Breaking Biology News(10 mins):
(Date:11/2/2019)... ... , ... A clinical trial usually involves many different parties, ... investigators, supply chain managers, manufacturers, IRT, CRAs and so on. Lack of communication ... potentially leading to patient risk. , By having a single source of truth, ...
(Date:10/30/2019)... ... October 30, 2019 , ... Western University of Health Sciences ... technology play in educating the next generation of health care providers. , The ... by WesternU administrators and representatives of companies working with the University on a ...
(Date:10/26/2019)... ... October 24, 2019 , ... Sparks ... Marketing Group (BMMG), a boutique healthcare-specific marketing firm, to strengthen the agency’s ... Healthcare Strategy Division. , Healthcare clients in pharma, bio-therapeutics, medical device and healthcare ...
(Date:10/22/2019)... ... October 22, 2019 , ... DermBiont, a clinical stage ... DBI-001, met its primary safety endpoints, with no application site reactions and no ... the treatment of interdigital tinea pedis (athlete’s foot). Additionally, the trial demonstrated a ...
Breaking Biology Technology:
Cached News: